Summary
82 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 16% a year over the last 3 years.
- The share price is below the Bulios Fair Price.
- Out of every 100 USD of revenue, 19 USD is left as net profit.
- It bought back its own shares for $881.0M in the last fiscal year, 9.3% of its market value.
What to watch
None of the indicators we track raises a caution right now.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 8.0 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
Revenue grew by 4.8% a year over 5 years. Over the last 3 years it grew by 4.7% a year. Earnings per share grew by 16% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 68 USD
- Sales and administration 5.3 USD
- Taxes and other -17 USD
- Net profit 19 USD
Net profit, industry median (Insurance - Life) 11 USD
Out of every 100 USD of revenue, 19 USD is left as net profit.
Profitability in detailIs it financially healthy?
Banks and insurers work with their customers' money, so their debt is judged differently; see the health section for their capital figures.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Life Segment 69%
- Health Segment 31%
By region
The company reports no revenue by region.
Life Segment brings in 69% of revenue. Health Segment grew fastest, by 6.2% a year.
Segments in detail